News NICE recommends Bayer drug for severe short-sightedness Eylea should be funded in mCNV, says NICE
Partner Content Partner Content 5 Key Reasons Why You Should Attend Europe's Leading Ophthal... 5 Key Reasons Why You Should Attend
News Novartis next generation eye drug outperforms Eylea Brolucizumab could offer quarterly dosing schedule.
News Novartis takes aim at Shire and Allergan with dry-eye drug Swiss company takes option on Lubris' ECF843.
News Shire looks to eye drug as sales beat forecasts Company reports better than expected full year figures.
News Takeda gets first OK for orexin narcolepsy drug, in China China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder narcolepsy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
